XML 42 R75.htm IDEA: XBRL DOCUMENT v3.19.3
Financial Information for Guarantor Subsidiaries and Non-Guarantor Subsidiaries - Supplemental Condensed Consolidating Statement of Cash Flows (Details) - USD ($)
$ in Millions
9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Condensed Financial Statements    
Net cash (used in) provided by operating activities $ 403 $ 356
Cash flows from investing activities:    
Capital expenditures (207) (293)
Acquisitions of businesses and assets, net of cash acquired 0 (274)
Distributions of capital from equity investments 18 24
Additions to equity method investments 1 76
Payments for (Proceeds from) Other Investing Activities   76
Other, principally change in intercompany investing activities 0 0
Net cash (used in) provided by investing activities (190) (619)
Cash flows from financing activities:    
Payments of long-term debt, net of proceeds (308) (30)
Repayment of assumed NYX debt 0 (288)
Payments of debt issuance and deferred financing costs (15) (39)
Payments on license obligations (26) (22)
Sale of future revenue 11  
Net proceeds from the sale of SciPlay common stock 342  
Payments of deferred SciPlay common stock offering costs (9) 0
Net redemptions of common stock under stock-based compensation plans and other (6) (24)
Other, principally change in intercompany financing activities 0 0
Net cash provided by (used in) financing activities (11) (403)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (1) (2)
Increase (decrease) in cash, cash equivalents and restricted cash 201 (668)
Cash, cash equivalents and restricted cash, beginning of period 220 834
Cash, cash equivalents and restricted cash, end of period 421 166
Reportable Legal Entities | SGI (Issuer)    
Condensed Financial Statements    
Net cash (used in) provided by operating activities 77 30
Cash flows from investing activities:    
Capital expenditures (22) (57)
Acquisitions of businesses and assets, net of cash acquired   0
Distributions of capital from equity investments 0 0
Additions to equity method investments 1  
Payments for (Proceeds from) Other Investing Activities   2
Other, principally change in intercompany investing activities 268 91
Net cash (used in) provided by investing activities 245 32
Cash flows from financing activities:    
Payments of long-term debt, net of proceeds (306) (24)
Repayment of assumed NYX debt   0
Payments of debt issuance and deferred financing costs (14) (39)
Payments on license obligations (1) 0
Sale of future revenue 0  
Net proceeds from the sale of SciPlay common stock 0  
Payments of deferred SciPlay common stock offering costs 0  
Net redemptions of common stock under stock-based compensation plans and other (2) 0
Other, principally change in intercompany financing activities 0 0
Net cash provided by (used in) financing activities (323) (63)
Effect of exchange rate changes on cash, cash equivalents and restricted cash 0 0
Increase (decrease) in cash, cash equivalents and restricted cash (1) (1)
Cash, cash equivalents and restricted cash, beginning of period 2 1
Cash, cash equivalents and restricted cash, end of period 1 0
Reportable Legal Entities | SGC (Parent)    
Condensed Financial Statements    
Net cash (used in) provided by operating activities (36) (56)
Cash flows from investing activities:    
Capital expenditures (17) (30)
Acquisitions of businesses and assets, net of cash acquired   0
Distributions of capital from equity investments 0 0
Additions to equity method investments 0  
Payments for (Proceeds from) Other Investing Activities   0
Other, principally change in intercompany investing activities 0 0
Net cash (used in) provided by investing activities (17) (30)
Cash flows from financing activities:    
Payments of long-term debt, net of proceeds 0 0
Repayment of assumed NYX debt   0
Payments of debt issuance and deferred financing costs 0 0
Payments on license obligations (20) (20)
Sale of future revenue 0  
Net proceeds from the sale of SciPlay common stock 0  
Payments of deferred SciPlay common stock offering costs 0  
Net redemptions of common stock under stock-based compensation plans and other 0 (22)
Other, principally change in intercompany financing activities 193 (565)
Net cash provided by (used in) financing activities 173 (607)
Effect of exchange rate changes on cash, cash equivalents and restricted cash 0 0
Increase (decrease) in cash, cash equivalents and restricted cash 120 (693)
Cash, cash equivalents and restricted cash, beginning of period 74 732
Cash, cash equivalents and restricted cash, end of period 194 39
Reportable Legal Entities | Guarantor Subsidiaries    
Condensed Financial Statements    
Net cash (used in) provided by operating activities 146 153
Cash flows from investing activities:    
Capital expenditures (85) (122)
Acquisitions of businesses and assets, net of cash acquired   (10)
Distributions of capital from equity investments 0 0
Additions to equity method investments 0  
Payments for (Proceeds from) Other Investing Activities   0
Other, principally change in intercompany investing activities (61) (15)
Net cash (used in) provided by investing activities (146) (147)
Cash flows from financing activities:    
Payments of long-term debt, net of proceeds 0 0
Repayment of assumed NYX debt   0
Payments of debt issuance and deferred financing costs 0 0
Payments on license obligations (5) (2)
Sale of future revenue 11  
Net proceeds from the sale of SciPlay common stock 0  
Payments of deferred SciPlay common stock offering costs 0  
Net redemptions of common stock under stock-based compensation plans and other (2) (2)
Other, principally change in intercompany financing activities 0 0
Net cash provided by (used in) financing activities 4 (4)
Effect of exchange rate changes on cash, cash equivalents and restricted cash 0 0
Increase (decrease) in cash, cash equivalents and restricted cash 4 2
Cash, cash equivalents and restricted cash, beginning of period 44 44
Cash, cash equivalents and restricted cash, end of period 48 46
Reportable Legal Entities | Non-Guarantor Subsidiaries    
Condensed Financial Statements    
Net cash (used in) provided by operating activities 216 231
Cash flows from investing activities:    
Capital expenditures (83) (84)
Acquisitions of businesses and assets, net of cash acquired   (264)
Distributions of capital from equity investments 18 24
Additions to equity method investments 0  
Payments for (Proceeds from) Other Investing Activities   74
Other, principally change in intercompany investing activities 0 0
Net cash (used in) provided by investing activities (65) (398)
Cash flows from financing activities:    
Payments of long-term debt, net of proceeds (2) (6)
Repayment of assumed NYX debt   (288)
Payments of debt issuance and deferred financing costs (1) 0
Payments on license obligations 0 0
Sale of future revenue 0  
Net proceeds from the sale of SciPlay common stock 342  
Payments of deferred SciPlay common stock offering costs (9)  
Net redemptions of common stock under stock-based compensation plans and other (2) 0
Other, principally change in intercompany financing activities (400) 489
Net cash provided by (used in) financing activities (72) 195
Effect of exchange rate changes on cash, cash equivalents and restricted cash (1) (2)
Increase (decrease) in cash, cash equivalents and restricted cash 78 26
Cash, cash equivalents and restricted cash, beginning of period 101 60
Cash, cash equivalents and restricted cash, end of period 179 86
Eliminating Entries    
Condensed Financial Statements    
Net cash (used in) provided by operating activities 0 (2)
Cash flows from investing activities:    
Capital expenditures 0 0
Acquisitions of businesses and assets, net of cash acquired   0
Distributions of capital from equity investments 0 0
Additions to equity method investments 0  
Payments for (Proceeds from) Other Investing Activities   0
Other, principally change in intercompany investing activities (207) (76)
Net cash (used in) provided by investing activities (207) (76)
Cash flows from financing activities:    
Payments of long-term debt, net of proceeds 0 0
Repayment of assumed NYX debt   0
Payments of debt issuance and deferred financing costs 0 0
Payments on license obligations 0 0
Sale of future revenue 0  
Net proceeds from the sale of SciPlay common stock 0  
Payments of deferred SciPlay common stock offering costs 0  
Net redemptions of common stock under stock-based compensation plans and other 0 0
Other, principally change in intercompany financing activities 207 76
Net cash provided by (used in) financing activities 207 76
Effect of exchange rate changes on cash, cash equivalents and restricted cash 0 0
Increase (decrease) in cash, cash equivalents and restricted cash 0 (2)
Cash, cash equivalents and restricted cash, beginning of period (1) (3)
Cash, cash equivalents and restricted cash, end of period $ (1) $ (5)